Page last updated: 2024-10-25

clobazam and Epilepsy

clobazam has been researched along with Epilepsy in 158 studies

Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.

Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)

Research Excerpts

ExcerptRelevanceReference
"Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive, socially acceptable route of administration."9.41Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study. ( Biton, V; Carrazana, E; Cascino, GD; Cook, DF; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021)
"Evaluation of the efficacy and side effects profile of Clobazam in a 24-week open-labelled trial involving 26 cases of drug naïve adult patients with epilepsy."9.10Clobazam monotherapy in drug naïve adult patients with epilepsy. ( Krishnamurthy, M; Mehndiratta, MM; Rajesh, KN; Singh, G, 2003)
"To compare the cognitive and behavioural effects of clobazam versus standard monotherapy in the treatment of childhood epilepsy."9.09The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. ( Bawden, HN; Camfield, CS; Camfield, PR; Cunningham, C; Darwish, H; Dooley, JM; Gordon, K; Ronen, G; Stewart, J; van Mastrigt, R, 1999)
"To compare the effectiveness of monotherapy clobazam (CLB) to carbamazepine (CBZ) and phenytoin (PHT) in children with epilepsy."9.08Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. ( , 1998)
"Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder."9.07Aggression in children treated with clobazam for epilepsy. ( Goulden, KJ; Ronen, GM; Sheth, RD, 1994)
"Clobazam, a novel benzodiazepine, was used as an add-on agent in 47 adult patients with intractable epilepsy and a variety of seizure types."9.06Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. ( Blaschuk, K; Couture, M; Guberman, A; Sherwin, A, 1990)
"We report the results of a double-blind cross-over study comparing clobazam and placebo in the treatment of refractory childhood epilepsy."9.06Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. ( Humphreys, P; Keene, DL; Whiting, S, 1990)
"The cyclical exacerbations of epilepsy (catamenial epilepsy) were used to assess the antiepileptic effect of a benzodiazepine, clobazam."9.05Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. ( Calvert, R; Feely, M; Gibson, J, 1982)
"The literature was reviewed to define the role of clobazam (CLB) in the treatment of epilepsy."8.79Clobazam in the treatment of epilepsy: a review of the literature. ( Remy, C, 1994)
"Clobazam (CLB), a 1,5-benzodiazepine, is a remarkably effective add-on drug for individual patients with refractory partial epilepsy."8.79Clobazam for treatment of intractable epilepsy: a critical assessment. ( Schmidt, D, 1994)
"To prospectively study the effectiveness and safety of clobazam as an add-on therapy in patients with epilepsy whose seizures are not adequately controlled with antiseizure medicine (ASM) monotherapy."8.12Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience. ( Agadi, J; Agarwal, VK; Alagesan, S; Apte, A; Arora, V; Asokan, K; Chauhan, D; Chodankar, D; Garg, S; Gurumukhani, J; Jha, SK; Kumar, A; Lingappa, L; Mandal, A; Menon, B; Padhy, U; Rathore, C; Ravat, S; Razdan, S; Satishchandra, P; Shah, SV; Shetty, S; Sundaracharya, NV; Venkateshwarlu, K; Vk, S, 2022)
" We review the use of short burst Clobazam dosing on discharge from the Epilepsy monitoring unit (EMU) to determine if this might reduce rates of representation with seizures."7.91Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures. ( Dionisio, S; Gillinder, L; Scarborough, L, 2019)
"Adult patients from Calgary's Comprehensive Epilepsy Program who were taking clobazam were approached to participate in the study."7.88A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy. ( Altura, KC; Jetté, N; Josephson, CB; Lukmanji, S; Sauro, KM; Wiebe, S, 2018)
"Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children."7.83The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016)
"To compare patient characteristics and treatment patterns among clobazam (CLB) and clonazepam (CZP)-treated patients with epilepsy in a longitudinal primary care database."7.83Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study. ( Brodie, MJ; Chung, S; François, C; Guiraud-Diawara, A; Isojarvi, J; Quelen, C; Shen, V; Verpillat, P; Wade, A, 2016)
"Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam."7.81Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015)
"Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children."7.81Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. ( Bruno, PL; Geffrey, AL; Pollack, SF; Thiele, EA, 2015)
"Clobazam has been used in clinical practice as an adjunctive treatment for diverse seizure types and epilepsy syndromes."7.80Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. ( Bergin, AM; Bolton, J; Bourgeois, B; Harini, C; Kadish, NE; Klehm, J; Libenson, M; Loddenkemper, T; Peters, J; Poduri, A; Rotenberg, A; Sánchez Fernández, I; Takeoka, M; Thome-Souza, S, 2014)
"The use of clobazam in epilepsy has increased since its introduction in 1975."7.80Effect of clobazam as add-on antiepileptic drug in patients with epilepsy. ( Gupta, P; Gupta, YK; Joshi, R; Tripathi, M, 2014)
"In treating refractory epilepsy, many clinicians are interested in methods used to transition patients receiving clonazepam to clobazam to maintain or increase seizure control, improve tolerability of patients' overall drug therapy regimens, and to enhance quality of life for patients and their families."7.80Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. ( Chung, S; Kuzniecky, R; Perry, MS; Sankar, R; Sinha, S, 2014)
"Clobazam (CLB) was recently approved by the FDA, but has not been evaluated in tuberous sclerosis complex (TSC)."7.79Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. ( Caruso, PA; Jennesson, M; Paolini, JL; Thiele, EA; van Eeghen, AM, 2013)
"An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)."7.78Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012)
"To evaluate the efficacy of clobazam in childhood refractory epilepsy and to characterize the adverse drug reaction profile in the Indian population."7.76Clobazam in refractory childhood epilepsy. ( Kalra, V; Mishra, D; Saha, NC; Seth, R, 2010)
"A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0."7.73Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. ( Aylett, SE; Berry, D; Cross, H, 2006)
" We report the first case observed in association with clobazam, used as adjunctive therapy for resistant epilepsy in a 4-year old."7.70Coma-induced bullae and sweat gland necrosis following clobazam. ( Calonje, E; MacDonald, D; Robinson, R; Setterfield, JF, 2000)
"Clobazam is a newer 1,5-benzodiazepine used for the treatment of epilepsy."7.70Clobazam for the treatment of intractable childhood epilepsy. ( Jan, MM; Shaabat, AO, 2000)
"We report our experience with add-on clobazam therapy over a 5-year period in 63 children with refractory epilepsy."7.69Clobazam for intractable pediatric epilepsy. ( Bodensteiner, JB; Goulden, KJ; Penney, S; Ronen, GM; Sheth, RD, 1995)
"We retrospectively collected plasma level assessments performed in 96 adult patients with epilepsy on stable monotherapy, including 9 patients on clobazam (CLB), 34 on carbamazepine (CBZ), 24 on phenobarbital (PB), 9 on phenytoin (PHT), and 20 on valproate (VPA); these results were compared to those obtained in 54 adult patients on stable bitherapy with the association of CLB with either CBZ (n = 17), PB (n = 17), PHT (n = 5), or VPA (n = 15)."7.68Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. ( Bonneton, J; Dravet, C; Genton, P; Mesdjian, E; Roger, J; Sennoune, S, 1992)
"Clobazam was added to the previous antiepileptic drug therapy of 90 children suffering from drug resistant epilepsy."7.68Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. ( Bardy, AH; Granström, ML; Salokorpi, T; Santavuori, P; Seppälä, T, 1991)
"Thirty drug-resistant epilepsy patients were given 20-30 mg of clobazam in addition to their other anticonvulsants and followed up for 2-3 years in an open-ended study."7.67The long-term effect of clobazam as adjunctive therapy in epilepsy. ( Moffett, A; Scott, DF, 1988)
"Sixteen patients with status epilepticus (SE) and 13 patients suffering from startle-induced epilepsy were treated with clobazam (CLB)."7.67Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. ( Aguglia, U; Gastaut, H; Tinuper, P, 1986)
" The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy."7.01Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023)
" Steady-state pharmacokinetic data are described from four healthy male volunteers and eight epileptic patients taking NDMC."6.66Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. ( Feely, MP; Haigh, JR; Peaker, S; Pullar, T, 1987)
"Clobazam is an oral 1,5-benzodiazepine used worldwide for the treatment of many types of epilepsies, although it is currently only approved for Lennox-Gastaut syndrome in the USA."6.52Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. ( Gauthier, AC; Mattson, RH, 2015)
"Clobazam is a promising antiepileptic medication, given its effectiveness and relatively low rates of adverse effects."6.48Clobazam for patients with Lennox-Gastaut syndrome and epilepsy. ( Ng, YT; Seif-Eddeine, H, 2012)
"Clobazam as an add-on treatment may reduce seizure frequency and may be most effective in partial onset seizures."6.44Clobazam as an add-on in the management of refractory epilepsy. ( Marson, AG; Michael, B, 2008)
"Several studies suggest antiseizure effects also beyond these three epilepsy syndromes."5.91Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. ( Bast, T; Becker, LL; Bertsche, A; Borggraefe, I; Boßelmann, CM; De Vries, H; Fahrbach, J; Hertzberg, C; Herz, NA; Hirsch, M; Holtkamp, M; Janello, C; Kaindl, AM; Klotz, KA; Kluger, GJ; Kühne, F; Kurlemann, G; Lerche, H; Makridis, KL; Prager, C; Pringsheim, M; Schubert-Bast, S; Schulz, J; Schulze-Bonhage, A; Steinbart, D; Steinhoff, BJ; Strzelczyk, A; Syrbe, S; von Podewils, F; Wagner, C; Wagner, J; Wilken, B, 2023)
"The average number of seizures per month during the previous 3 months before CNB treatment was 19."5.91Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023)
"Here, one such patient became seizure free, allowing us to identify and compare the changes in hippocampal electrophysiology associated with ANT stimulation and seizure freedom."5.91Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023)
"Clobazam is an effective agent to use as add-on AED in TRE, with 94% of patients showing a significant response within 6 months."5.62Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy. ( Bachman, E; Brahmbhatt, N; Bushara, O; Schuele, SU; Stupp, R; Templer, JW, 2021)
"Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures."5.48Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018)
"Pharmacokinetic variability of CLB in pediatric patients is extensive, and it is influenced by drug-drug interactions and age."5.48Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy. ( Phelps, SJ; Russell, GR; Shelton, CM; Wheless, JW, 2018)
"5 mg/day) and dosage increased until N-CLB serum concentration reaches 1100 ng/mL or until the desired effect is acquired, a recommendation that is particularly important for PMs."5.42Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. ( Hashi, S; Ikeda, A; Kinoshita, M; Masuda, S; Matsubara, K; Matsumoto, R; Shibata, M; Takahashi, R; Yano, I, 2015)
"Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive, socially acceptable route of administration."5.41Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study. ( Biton, V; Carrazana, E; Cascino, GD; Cook, DF; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021)
"Clobazam (CLB) is a 1,5-benzodiazepine with antiepileptic properties."5.40Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. ( Ishitsu, T; Kaneko, S; Nagata, R; Nakagawa, K; Nakashima, H; Nishimura, M; Ogusu, N; Saruwatari, J; Seo, T; Shimomasuda, M; Tanikawa, K; Tsuda, Y; Yasui-Furukori, N, 2014)
"Clobazam has efficacy against a wide spectrum of seizure types and epilepsy etiologies."5.39Clobazam for the treatment of intractable epilepsy in children. ( Bailey, L; Gilson, C; Hernandez, A; Kotecha, A; Malik, S; Perry, MS, 2013)
"Clobazam (CLB) is a structurally unique benzodiazepine (BZD) that has anticonvulsant activity in all types of refractory seizures."5.29Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance. ( Boisvert, D; Guberman, AH; Singh, A, 1995)
" Cannabidiol (CBD) is increasingly used to treat epilepsy."5.12Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients. ( Główka, AK; Główka, FK; Karaźniewicz-Łada, M; Mikulska, AA, 2021)
"Evaluation of the efficacy and side effects profile of Clobazam in a 24-week open-labelled trial involving 26 cases of drug naïve adult patients with epilepsy."5.10Clobazam monotherapy in drug naïve adult patients with epilepsy. ( Krishnamurthy, M; Mehndiratta, MM; Rajesh, KN; Singh, G, 2003)
"To compare the cognitive and behavioural effects of clobazam versus standard monotherapy in the treatment of childhood epilepsy."5.09The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. ( Bawden, HN; Camfield, CS; Camfield, PR; Cunningham, C; Darwish, H; Dooley, JM; Gordon, K; Ronen, G; Stewart, J; van Mastrigt, R, 1999)
"To compare the effectiveness of monotherapy clobazam (CLB) to carbamazepine (CBZ) and phenytoin (PHT) in children with epilepsy."5.08Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. ( , 1998)
"Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder."5.07Aggression in children treated with clobazam for epilepsy. ( Goulden, KJ; Ronen, GM; Sheth, RD, 1994)
"Clobazam, a novel benzodiazepine, was used as an add-on agent in 47 adult patients with intractable epilepsy and a variety of seizure types."5.06Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. ( Blaschuk, K; Couture, M; Guberman, A; Sherwin, A, 1990)
"We report the results of a double-blind cross-over study comparing clobazam and placebo in the treatment of refractory childhood epilepsy."5.06Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. ( Humphreys, P; Keene, DL; Whiting, S, 1990)
"The cyclical exacerbations of epilepsy (catamenial epilepsy) were used to assess the antiepileptic effect of a benzodiazepine, clobazam."5.05Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. ( Calvert, R; Feely, M; Gibson, J, 1982)
"The literature was reviewed to define the role of clobazam (CLB) in the treatment of epilepsy."4.79Clobazam in the treatment of epilepsy: a review of the literature. ( Remy, C, 1994)
"Clobazam (CLB), a 1,5-benzodiazepine, is a remarkably effective add-on drug for individual patients with refractory partial epilepsy."4.79Clobazam for treatment of intractable epilepsy: a critical assessment. ( Schmidt, D, 1994)
" Clonazepam, chlorazepate, nitrazepam and clobazam are also prescribed as chronic treatment of various forms of epilepsy."4.76[Benzodiazepines in the treatment of epilepsy]. ( Loiseau, P, 1983)
"We identified a significant decrease in the serum concentrations of clobazam, desmethylclobazam, and lamotrigine following a 12-week ketogenic diet intervention in children with drug resistant epilepsy."4.31Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet. ( Gervin, K; Iversen, PO; Kverneland, M; Landmark, CJ; Pedersen, S; Rudi, K; Selmer, KK, 2023)
"To prospectively study the effectiveness and safety of clobazam as an add-on therapy in patients with epilepsy whose seizures are not adequately controlled with antiseizure medicine (ASM) monotherapy."4.12Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience. ( Agadi, J; Agarwal, VK; Alagesan, S; Apte, A; Arora, V; Asokan, K; Chauhan, D; Chodankar, D; Garg, S; Gurumukhani, J; Jha, SK; Kumar, A; Lingappa, L; Mandal, A; Menon, B; Padhy, U; Rathore, C; Ravat, S; Razdan, S; Satishchandra, P; Shah, SV; Shetty, S; Sundaracharya, NV; Venkateshwarlu, K; Vk, S, 2022)
"Clobazam (CLB) is an effective anticonvulsant used as an adjunctive treatment for several seizures and epilepsy syndromes."4.12CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up. ( Öztürk, G; Türkdoğan, D, 2022)
" We review the use of short burst Clobazam dosing on discharge from the Epilepsy monitoring unit (EMU) to determine if this might reduce rates of representation with seizures."3.91Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures. ( Dionisio, S; Gillinder, L; Scarborough, L, 2019)
"Adult patients from Calgary's Comprehensive Epilepsy Program who were taking clobazam were approached to participate in the study."3.88A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy. ( Altura, KC; Jetté, N; Josephson, CB; Lukmanji, S; Sauro, KM; Wiebe, S, 2018)
"Serum concentration measurements of CLB and its metabolite N-desmethylclobazam (NCLB), as well as demographic and clinical data were retrieved from the routine therapeutic drug monitoring service at the National Center for Epilepsy, Norway, 2009-2013."3.83Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability. ( Baftiu, A; Burns, ML; Johannessen, SI; Landmark, CJ; Opdal, MS, 2016)
"Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children."3.83The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016)
"To compare patient characteristics and treatment patterns among clobazam (CLB) and clonazepam (CZP)-treated patients with epilepsy in a longitudinal primary care database."3.83Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study. ( Brodie, MJ; Chung, S; François, C; Guiraud-Diawara, A; Isojarvi, J; Quelen, C; Shen, V; Verpillat, P; Wade, A, 2016)
"The alterations observed in body composition with valproic acid in contrast to other AEDs like levetiracetam, carbamazepine and phenytoin could affect treatment response in epilepsy especially in subjects with already altered body composition status like obese and thin frail patients, which needs to be established by prospective studies (CTRI/2013/05/003701)."3.83Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs. ( Gupta, YK; Kakkar, AK; Sarangi, SC; Tripathi, M, 2016)
"Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam."3.81Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015)
"Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children."3.81Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. ( Bruno, PL; Geffrey, AL; Pollack, SF; Thiele, EA, 2015)
"Clobazam has been used in clinical practice as an adjunctive treatment for diverse seizure types and epilepsy syndromes."3.80Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. ( Bergin, AM; Bolton, J; Bourgeois, B; Harini, C; Kadish, NE; Klehm, J; Libenson, M; Loddenkemper, T; Peters, J; Poduri, A; Rotenberg, A; Sánchez Fernández, I; Takeoka, M; Thome-Souza, S, 2014)
"The use of clobazam in epilepsy has increased since its introduction in 1975."3.80Effect of clobazam as add-on antiepileptic drug in patients with epilepsy. ( Gupta, P; Gupta, YK; Joshi, R; Tripathi, M, 2014)
"In treating refractory epilepsy, many clinicians are interested in methods used to transition patients receiving clonazepam to clobazam to maintain or increase seizure control, improve tolerability of patients' overall drug therapy regimens, and to enhance quality of life for patients and their families."3.80Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. ( Chung, S; Kuzniecky, R; Perry, MS; Sankar, R; Sinha, S, 2014)
"Clobazam (CLB) was recently approved by the FDA, but has not been evaluated in tuberous sclerosis complex (TSC)."3.79Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. ( Caruso, PA; Jennesson, M; Paolini, JL; Thiele, EA; van Eeghen, AM, 2013)
"An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)."3.78Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012)
"To evaluate the efficacy of clobazam in childhood refractory epilepsy and to characterize the adverse drug reaction profile in the Indian population."3.76Clobazam in refractory childhood epilepsy. ( Kalra, V; Mishra, D; Saha, NC; Seth, R, 2010)
"To assess the molecular effects of the antiepileptic drug clobazam (CLB, 1,5-benzodiazepine), a benzodiazepine effective in the management of epilepsy, we performed a series of experiments using rats with chronic, spontaneous recurrent seizures induced by amygdalar injection of FeCl(3)."3.73Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. ( Doi, T; Tokumaru, J; Ueda, Y; Willmore, LJ, 2005)
"Clobazam has been used successfully in adults and children with partial epilepsy."3.73Clobazam as add-on therapy in children with epileptic encephalopathy. ( Guerreiro, CA; Guerreiro, MM; Montenegro, MA; Silva, RC, 2006)
"A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0."3.73Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. ( Aylett, SE; Berry, D; Cross, H, 2006)
"Morning urine samples were collected from children with epilepsy receiving VPA (n = 25), carbamazepine (n = 16), or clobazam (n = 12) for > or = 4 weeks and from age-matched control subjects (n = 39)."3.73Oxidative stress in children receiving valproic acid. ( Abbott, FS; Chang, TK; Farrell, K; Michoulas, A; Teng, XW; Tong, V, 2006)
" We report the first case observed in association with clobazam, used as adjunctive therapy for resistant epilepsy in a 4-year old."3.70Coma-induced bullae and sweat gland necrosis following clobazam. ( Calonje, E; MacDonald, D; Robinson, R; Setterfield, JF, 2000)
"Clobazam is a newer 1,5-benzodiazepine used for the treatment of epilepsy."3.70Clobazam for the treatment of intractable childhood epilepsy. ( Jan, MM; Shaabat, AO, 2000)
"We report our experience with add-on clobazam therapy over a 5-year period in 63 children with refractory epilepsy."3.69Clobazam for intractable pediatric epilepsy. ( Bodensteiner, JB; Goulden, KJ; Penney, S; Ronen, GM; Sheth, RD, 1995)
"The development of tolerance to the anticonvulsant effects of clonazepam, clobazam, and diazepam were studied in genetically epilepsy-prone rats following intraperitoneal (IP) or oral administration."3.69Tolerance to anticonvulsant effects of some benzodiazepines in genetically epilepsy prone rats. ( Aguglia, U; de Sarro, A; De Sarro, G; Di Paola, ED, 1996)
"We present the study of 20 pediatric patients with difficult controlled epilepsy in which we used clobazam as adjuvant anticonvulsant therapy between January 1986 and July 1990 at the outpatients neuropediatric facility of the Hospital General Base Cayetano Heredia and the private practice, with 6 to 45 months follow up."3.68[Clobazam use in refractory epilepsies in children]. ( Campos, P, 1993)
"We retrospectively collected plasma level assessments performed in 96 adult patients with epilepsy on stable monotherapy, including 9 patients on clobazam (CLB), 34 on carbamazepine (CBZ), 24 on phenobarbital (PB), 9 on phenytoin (PHT), and 20 on valproate (VPA); these results were compared to those obtained in 54 adult patients on stable bitherapy with the association of CLB with either CBZ (n = 17), PB (n = 17), PHT (n = 5), or VPA (n = 15)."3.68Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. ( Bonneton, J; Dravet, C; Genton, P; Mesdjian, E; Roger, J; Sennoune, S, 1992)
"Tolerance to the anticonvulsant effects of clobazam has been studied in three murine models of epilepsy: pentylenetetrazole- and N-methyl-D,L-aspartic acid-induced seizures and audiogenic-induced seizures in the DBA/2 strain."3.68Tolerance to the anticonvulsant effects of clobazam in mice. ( Pleuvry, BJ; Wildin, JD, 1992)
"Clobazam was added to the previous antiepileptic drug therapy of 90 children suffering from drug resistant epilepsy."3.68Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. ( Bardy, AH; Granström, ML; Salokorpi, T; Santavuori, P; Seppälä, T, 1991)
"Oxiracetam, a nootropic drug, could be of potential use in the treatment of memory disturbances in patients with epilepsy who are using antiepileptic drugs."3.68Pilot study to determine the interaction of oxiracetam with antiepileptic drugs. ( Meijer, JW; van Emde Boas, W; van Wieringen, A; Vermeij, TA, 1990)
"Thirty drug-resistant epilepsy patients were given 20-30 mg of clobazam in addition to their other anticonvulsants and followed up for 2-3 years in an open-ended study."3.67The long-term effect of clobazam as adjunctive therapy in epilepsy. ( Moffett, A; Scott, DF, 1988)
"Sixteen patients with status epilepticus (SE) and 13 patients suffering from startle-induced epilepsy were treated with clobazam (CLB)."3.67Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. ( Aguglia, U; Gastaut, H; Tinuper, P, 1986)
"Preliminary studies of patients who had brain damage, intractable epilepsy, and mental subnormality showed that clobazam in small doses (20 to 30 mg/day) was beneficial, and indicated that a more detailed investigation was worthwhile."3.67On the anticonvulsant and psychotropic properties of clobazam--a preliminary study. ( Moffett, A; Scott, DF, 1986)
" The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy."3.01Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023)
"Clobazam was well tolerated and reduced drop seizure rates; high-dose CLB was more effective than low-dose CLB."2.74Clobazam in the treatment of Lennox-Gastaut syndrome. ( Abdulnabi, R; Collins, SD; Conry, JA; Kernitsky, L; Kormany, WN; Mitchell, WG; Ng, YT; Paolicchi, JM; Riley, B; Ritter, FJ; Stolle, J; Tracy, K, 2009)
"Clobazam was used as an added treatment in 28 patients with intractable epilepsies: 26 subjects had associated handicaps."2.66Intractable epilepsies. An open trial with Clobazam. ( Cattabeni, G; Cerisola, N; Cornaggia, CM; Leozappa, C; Manghi, E; Mascetti, PL; Massironi, R; Porro, G, 1989)
" Steady-state pharmacokinetic data are described from four healthy male volunteers and eight epileptic patients taking NDMC."2.66Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. ( Feely, MP; Haigh, JR; Peaker, S; Pullar, T, 1987)
"Clobazam has nitrogen radicals in positions 1 and 5."2.65Antiepileptic effects of clobazam in children. ( Abe, J; Futagi, Y; Kamio, M; Kato, M; Mimaki, T; Onoe, S; Shimizu, H; Sugita, T; Sumi, K; Tagawa, T; Yabuuchi, H; Yamatodani, A, 1982)
"Clobazam is an oral 1,5-benzodiazepine used worldwide for the treatment of many types of epilepsies, although it is currently only approved for Lennox-Gastaut syndrome in the USA."2.52Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. ( Gauthier, AC; Mattson, RH, 2015)
"Clobazam is a promising antiepileptic medication, given its effectiveness and relatively low rates of adverse effects."2.48Clobazam for patients with Lennox-Gastaut syndrome and epilepsy. ( Ng, YT; Seif-Eddeine, H, 2012)
"Clobazam has demonstrated clinical benefit and has been administered safely in more than 50 European studies in which data were reported on greater than 3000 pediatric and adult patients with epilepsy, 300 of whom were diagnosed with LGS; therefore, its use is now being investigated in the U."2.44Clobazam. ( Collins, SD; Ng, YT, 2007)
"Clobazam as an add-on treatment may reduce seizure frequency and may be most effective in partial onset seizures."2.44Clobazam as an add-on in the management of refractory epilepsy. ( Marson, AG; Michael, B, 2008)
"The former consists mainly of severe myoclonic epilepsy in infancy (SMEN), in which patients exhibit seizures from the middle of the first year of life with repeated episodes of status epilepticus, and migrating partial epilepsy in infancy, in which, from the first trimester of life, partial seizures affect various areas of the cortex randomly and in a subcontinuous fashion."2.41Epileptic encephalopathy. ( Dulac, O, 2001)
"Clobazam (CLB) is a new antiepileptic drug that is the first 1,5-benzodiazepine (BZP) having nitrogen atoms in the 1 and 5 positions of the heterocyclic ring, whose chemical structure was designed to give it a different pharmacological profile from that of 1,4-BZPs."2.41[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]. ( Nakajima, H, 2001)
"Several studies suggest antiseizure effects also beyond these three epilepsy syndromes."1.91Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. ( Bast, T; Becker, LL; Bertsche, A; Borggraefe, I; Boßelmann, CM; De Vries, H; Fahrbach, J; Hertzberg, C; Herz, NA; Hirsch, M; Holtkamp, M; Janello, C; Kaindl, AM; Klotz, KA; Kluger, GJ; Kühne, F; Kurlemann, G; Lerche, H; Makridis, KL; Prager, C; Pringsheim, M; Schubert-Bast, S; Schulz, J; Schulze-Bonhage, A; Steinbart, D; Steinhoff, BJ; Strzelczyk, A; Syrbe, S; von Podewils, F; Wagner, C; Wagner, J; Wilken, B, 2023)
"The average number of seizures per month during the previous 3 months before CNB treatment was 19."1.91Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023)
"Here, one such patient became seizure free, allowing us to identify and compare the changes in hippocampal electrophysiology associated with ANT stimulation and seizure freedom."1.91Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023)
"A positive response (seizure-free and >50 % seizure reduction) was determined for focal-onset (62."1.72The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study. ( Arslan, EA; Aydın, K; Cansu, A; Çarman, KB; Dilber, B; Dündar, NO; Durgut, BD; Erdoğan, I; Gencpinar, P; Hız, SA; Kamaşak, T; Kılıç, BA; Okuyaz, Ç; Özen, N; Özkan Kart, P; Polat, BG; Şahin, S; Serdaroğlu, A; Serdaroğlu, E; Serin, HM; Tekgül, H; Topçu, Y; Yıldız, N; Yılmaz, Ö; Yücel Şen, AD, 2022)
" VPA showed a relatively short half-life in both mice and rats, which correlated with a sharp decline in efficacy."1.72Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach. ( Johnson, K; Mensah, JA; Metcalf, CS; Reilly, CA; Rower, JE; Wilcox, KS, 2022)
"Clobazam is an effective agent to use as add-on AED in TRE, with 94% of patients showing a significant response within 6 months."1.62Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy. ( Bachman, E; Brahmbhatt, N; Bushara, O; Schuele, SU; Stupp, R; Templer, JW, 2021)
" The aim was to use long-term TDM to investigate pharmacokinetic variability of ASMs in these patients."1.56Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome. ( Bjørnvold, M; Burns, ML; Heger, K; Johannessen Landmark, C; Johannessen, SI; Lund, C; Sætre, E, 2020)
"Epilepsy is very difficult to treat and often involves the combination of two or more AEDs."1.56Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database. ( Hayashi, T; Noguchi, Y; Tachi, T; Takaoka, M; Teramachi, H, 2020)
"Clobazam is a 1,5-benzodiazepine that has been approved for use, in various parts of the world, as an add-on treatment for seizure disorders and as a treatment for anxiety."1.51Gestational Exposure to Benzodiazepines, 3: Clobazam and Major Congenital Malformations. ( Andrade, C, 2019)
"Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures."1.48Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018)
"Pharmacokinetic variability of CLB in pediatric patients is extensive, and it is influenced by drug-drug interactions and age."1.48Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy. ( Phelps, SJ; Russell, GR; Shelton, CM; Wheless, JW, 2018)
"5 mg/day) and dosage increased until N-CLB serum concentration reaches 1100 ng/mL or until the desired effect is acquired, a recommendation that is particularly important for PMs."1.42Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. ( Hashi, S; Ikeda, A; Kinoshita, M; Masuda, S; Matsubara, K; Matsumoto, R; Shibata, M; Takahashi, R; Yano, I, 2015)
"Clobazam (CLB) is a 1,5-benzodiazepine with antiepileptic properties."1.40Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. ( Ishitsu, T; Kaneko, S; Nagata, R; Nakagawa, K; Nakashima, H; Nishimura, M; Ogusu, N; Saruwatari, J; Seo, T; Shimomasuda, M; Tanikawa, K; Tsuda, Y; Yasui-Furukori, N, 2014)
"Psychosis is more common in people with temporal lobe epilepsy than it is in the general population."1.39Electroconvulsive therapy for psychosis in a patient with epilepsy related to hypothalamic hamartoma. ( Foucher, J; Hirsch, E; Lalanne, L; Ruppert, E; Vidailhet, P; Zimmermann, MA, 2013)
"Clobazam has efficacy against a wide spectrum of seizure types and epilepsy etiologies."1.39Clobazam for the treatment of intractable epilepsy in children. ( Bailey, L; Gilson, C; Hernandez, A; Kotecha, A; Malik, S; Perry, MS, 2013)
"Clobazam is a 1,5-benzodiazepine effective in antiepileptic therapy of children and adults."1.30Interactions of clobazam with conventional antiepileptics in children. ( Cortez, M; Daneman, R; Hwang, P; Koren, G; Menzano, E; Sherwin, AL; Theis, JG, 1997)
" Both CBZ and CBZ-epoxide (CBZ-E) blood levels were elevated, and the symptoms resolved quickly when CBZ dosage was reduced and CLB discontinued."1.30Carbamazepine intoxication with negative myoclonus after the addition of clobazam. ( Genton, P; Mesdjian, E; Nguyen, VH, 1998)
"Clobazam (CLB) is a structurally unique benzodiazepine (BZD) that has anticonvulsant activity in all types of refractory seizures."1.29Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance. ( Boisvert, D; Guberman, AH; Singh, A, 1995)
"Clobazam was administered in 13 patients; 15."1.27Startle-induced epileptic seizures. ( Aguglia, U; Gastaut, H; Tinuper, P, 1984)
"Ethosuximide was quantitated by gas chromatography."1.27Tissue distribution of ethosuximide and clobazam in a seizure related fatality. ( Fraser, AD; Heifetz, SA; Isner, AF, 1988)

Research

Studies (158)

TimeframeStudies, this research(%)All Research%
pre-199037 (23.42)18.7374
1990's39 (24.68)18.2507
2000's25 (15.82)29.6817
2010's38 (24.05)24.3611
2020's19 (12.03)2.80

Authors

AuthorsStudies
Karaźniewicz-Łada, M1
Główka, AK1
Mikulska, AA1
Główka, FK1
Satishchandra, P2
Rathore, C1
Apte, A1
Kumar, A1
Mandal, A1
Chauhan, D1
Agadi, J1
Gurumukhani, J1
Asokan, K1
Venkateshwarlu, K1
Lingappa, L1
Sundaracharya, NV1
Jha, SK1
Ravat, S1
Vk, S1
Garg, S1
Shah, SV1
Alagesan, S1
Razdan, S1
Padhy, U1
Agarwal, VK1
Arora, V1
Menon, B1
Shetty, S1
Chodankar, D1
Kamaşak, T1
Serdaroğlu, E1
Yılmaz, Ö1
Kılıç, BA1
Polat, BG1
Erdoğan, I1
Yücel Şen, AD1
Özen, N1
Durgut, BD1
Yıldız, N1
Özkan Kart, P1
Dilber, B1
Arslan, EA1
Şahin, S1
Topçu, Y1
Gencpinar, P1
Serin, HM1
Hız, SA1
Çarman, KB1
Dündar, NO1
Okuyaz, Ç1
Aydın, K1
Serdaroğlu, A1
Tekgül, H1
Cansu, A1
Mensah, JA1
Johnson, K1
Reilly, CA1
Wilcox, KS1
Rower, JE1
Metcalf, CS1
Tomson, T1
Battino, D1
Bromley, R1
Kochen, S1
Meador, KJ1
Pennell, PB1
Thomas, SV1
Talwar, A1
Estes, E1
Aparasu, R1
Reddy, DS1
Kühne, F1
Becker, LL1
Bast, T1
Bertsche, A1
Borggraefe, I1
Boßelmann, CM1
Fahrbach, J1
Hertzberg, C1
Herz, NA1
Hirsch, M1
Holtkamp, M1
Janello, C1
Kluger, GJ1
Kurlemann, G1
Lerche, H1
Makridis, KL1
von Podewils, F1
Pringsheim, M1
Schubert-Bast, S1
Schulz, J1
Schulze-Bonhage, A1
Steinbart, D1
Steinhoff, BJ1
Strzelczyk, A1
Syrbe, S1
De Vries, H1
Wagner, C1
Wagner, J1
Wilken, B1
Prager, C1
Klotz, KA1
Kaindl, AM1
Riva, A1
Roberti, R1
D'Onofrio, G1
Vari, MS1
Amadori, E1
De Giorgis, V1
Cerminara, C1
Specchio, N2
Pietrafusa, N1
Tombini, M1
Assenza, G1
Cappanera, S1
Marini, C1
Rasmini, P1
Veggiotti, P2
Zara, F1
Russo, E1
Striano, P1
Pedersen, S1
Kverneland, M1
Rudi, K1
Gervin, K1
Landmark, CJ2
Iversen, PO1
Selmer, KK1
Serrano-Castro, PJ1
Rodríguez-Uranga, JJ1
Cabezudo-García, P1
García-Martín, G1
Romero-Godoy, J1
Estivill-Torrús, G1
Ciano-Petersen, NL1
Oliver, B1
Ortega-Pinazo, J1
López-Moreno, Y1
Aguilar-Castillo, MJ1
Gutierrez-Cardo, AL1
Ramírez-García, T1
Sanchez-Godoy, L1
Carreño, M1
Skelton, HM1
Brandman, DM1
Bullinger, K1
Isbaine, F1
Gross, RE1
Andrade, C1
Deng, L1
Ma, A1
Wood, N1
Ardern-Holmes, S1
Johannessen Landmark, C1
Heger, K1
Lund, C1
Burns, ML2
Bjørnvold, M1
Sætre, E1
Johannessen, SI2
VanLandingham, KE1
Crockett, J1
Taylor, L1
Morrison, G1
Noguchi, Y1
Takaoka, M1
Hayashi, T1
Tachi, T1
Teramachi, H1
van den Munckhof, B1
Arzimanoglou, A1
Perucca, E1
van Teeseling, HC1
Leijten, FSS1
Braun, KPJ1
Jansen, FE1
Brahmbhatt, N1
Stupp, R1
Bushara, O1
Bachman, E1
Schuele, SU1
Templer, JW1
Türkdoğan, D1
Öztürk, G1
Segal, EB1
Tarquinio, D1
Miller, I1
Wheless, JW2
Dlugos, D1
Biton, V1
Cascino, GD1
Desai, J1
Hogan, RE1
Liow, K1
Sperling, MR1
Vazquez, B1
Cook, DF1
Rabinowicz, AL1
Carrazana, E1
Gaston, TE1
Bebin, EM1
Cutter, GR1
Liu, Y1
Szaflarski, JP1
Vega, C1
Sánchez Fernández, I2
Peters, J2
Thome-Souza, MS1
Jackson, M1
Takeoka, M2
Wilkening, GN1
Pearl, PL1
Chapman, K1
Loddenkemper, T2
Lukmanji, S1
Sauro, KM1
Josephson, CB1
Altura, KC1
Wiebe, S1
Jetté, N1
Porcari, GS1
Fu, C1
Doll, ED1
Carter, EG1
Carson, RP1
Skarpaas, TL1
Tcheng, TK1
Morrell, MJ1
Russell, GR1
Phelps, SJ1
Shelton, CM1
Galappatthy, P1
Liyanage, CK1
Lucas, MN1
Jayasekara, DTLM1
Abhayaratna, SA1
Weeraratne, C1
De Abrew, K1
Gunaratne, PS1
Gamage, R1
Wijeyaratne, CN1
Gillinder, L1
Scarborough, L1
Dionisio, S1
Yamamoto, Y3
Takahashi, Y3
Imai, K3
Miyakawa, K1
Nishimura, S2
Kasai, R1
Ikeda, H1
Takayama, R1
Mogami, Y2
Yamaguchi, T1
Terada, K2
Matsuda, K2
Inoue, Y3
Kagawa, Y3
Ruppert, E1
Lalanne, L1
Foucher, J1
Zimmermann, MA1
Hirsch, E1
Vidailhet, P1
Saruwatari, J1
Ogusu, N1
Shimomasuda, M1
Nakashima, H1
Seo, T1
Tanikawa, K1
Tsuda, Y1
Nishimura, M1
Nagata, R1
Yasui-Furukori, N1
Kaneko, S1
Ishitsu, T1
Nakagawa, K1
Nakai, M2
Klehm, J1
Thome-Souza, S1
Bergin, AM1
Bolton, J1
Harini, C1
Kadish, NE1
Libenson, M1
Poduri, A1
Rotenberg, A1
Bourgeois, B1
Dilipkumar, S1
Subbakrishna, DK1
Sinha, S2
Takahashi, M1
Tan, HJ1
Singh, J1
Gupta, R1
de Goede, C1
Guerreiro, CA2
Joshi, R1
Tripathi, M2
Gupta, P1
Gupta, YK2
Hashi, S1
Yano, I1
Shibata, M1
Masuda, S1
Kinoshita, M2
Matsumoto, R1
Ikeda, A2
Takahashi, R1
Matsubara, K1
Trivisano, M1
Vigevano, F1
Sankar, R1
Chung, S2
Perry, MS2
Kuzniecky, R1
Gauthier, AC1
Mattson, RH1
Geffrey, AL1
Pollack, SF1
Bruno, PL1
Thiele, EA2
Baftiu, A1
Opdal, MS1
Mathew, T1
D'Souza, D1
Nadimpally, US1
Nadig, R1
Takeuchi, T1
Natsume, J1
Kidokoro, H1
Ishihara, N1
Yamamoto, H1
Azuma, Y1
Ito, Y1
Kurahashi, N1
Tsuji, T1
Suzuki, M1
Itomi, K1
Yamada, K1
Kurahashi, H1
Abe, S1
Okumura, A1
Maruyama, K1
Negoro, T1
Watanabe, K1
Kojima, S1
Brodie, MJ3
Wade, A1
Quelen, C1
Guiraud-Diawara, A1
François, C1
Verpillat, P1
Shen, V1
Isojarvi, J1
Sarangi, SC1
Kakkar, AK1
Hawkins, NA1
Zachwieja, NJ1
Miller, AR1
Anderson, LL1
Kearney, JA1
Conry, JA1
Ng, YT3
Paolicchi, JM1
Kernitsky, L1
Mitchell, WG1
Ritter, FJ1
Collins, SD2
Tracy, K1
Kormany, WN1
Abdulnabi, R1
Riley, B1
Stolle, J1
Kalra, V1
Seth, R1
Mishra, D1
Saha, NC1
Wolf, P1
Mills, JK1
Lewis, TG1
Mughal, K1
Ali, I1
Ugur, A1
Whitehouse, WP1
Seif-Eddeine, H1
Nabbout, R1
Chiron, C1
Bailey, L1
Malik, S1
Gilson, C1
Kotecha, A1
Hernandez, A1
Jennesson, M1
van Eeghen, AM1
Caruso, PA1
Paolini, JL1
Maschio, M1
Dinapoli, L1
Sperati, F1
Pace, A1
Fabi, A1
Vidiri, A1
Pompili, A1
Carapella, CM1
Arvio, M1
Sipilä, I1
Kurokawa, T1
Héberlé, C1
Berquin, P1
Larnicol, N1
Wallois, F1
Mehndiratta, MM1
Krishnamurthy, M1
Rajesh, KN1
Singh, G1
Parmeggiani, A1
Posar, A1
Sangiorgi, S1
Giovanardi-Rossi, P1
Kosaki, K1
Tamura, K1
Sato, R1
Samejima, H1
Tanigawara, Y1
Takahashi, T1
Sugai, K1
Cardinali, S1
Granocchio, E1
Avantaggiato, P1
Papalia, G1
Cagnana, A1
Lanzi, G1
Doi, T1
Ueda, Y1
Tokumaru, J1
Willmore, LJ1
Silva, RC1
Montenegro, MA1
Guerreiro, MM1
Aylett, SE1
Cross, H1
Berry, D1
Michoulas, A1
Tong, V1
Teng, XW1
Chang, TK1
Abbott, FS1
Farrell, K2
von Wrede, R1
Begum, T1
Shibasaki, H1
Michael, B1
Marson, AG2
Feely, M4
Calvert, R1
Gibson, J2
Gastaut, H3
Dulac, O2
Figueroa, D1
Rey, E1
Arthuis, M1
Loiseau, P1
Callaghan, N2
Goggin, T2
Allen, JW2
Oxley, J3
Robertson, MM2
Trimble, MR4
Richens, A2
Jawad, SS1
Aguglia, U3
Tinuper, P2
Gyuris, J1
Csémi, K1
Jawad, S2
Wilson, A1
Petty, R1
Perry, A1
Rose, FC1
Hertrich, O1
Shimizu, H1
Abe, J1
Futagi, Y1
Onoe, S1
Tagawa, T1
Mimaki, T1
Yamatodani, A1
Kato, M1
Kamio, M1
Sumi, K1
Sugita, T1
Yabuuchi, H1
Tedeschi, G2
Riva, R2
Baruzzi, A2
Albani, F1
Singh, A1
Guberman, AH1
Boisvert, D1
Sheth, RD2
Ronen, GM2
Goulden, KJ2
Penney, S1
Bodensteiner, JB1
O'Neill, BA1
Bloom, DS1
Buchanan, N2
Remy, C1
Schmidt, D1
Campos, P1
Shields, WD1
Duncan, S1
Gillen, GJ1
Larkin, JG1
McKee, PJ1
Thompson, GG1
Salt, SD1
Boyd, K1
Nakamura, F1
Suzuki, S1
Yagi, K1
Seino, M1
Fisher, R1
Blum, D1
De Sarro, G1
Di Paola, ED1
de Sarro, A2
Grippo, J1
Theis, JG1
Koren, G1
Daneman, R1
Sherwin, AL1
Menzano, E1
Cortez, M1
Hwang, P1
De Sarro, GB2
Berlinghieri, MC1
Elia, M1
Musumeci, SA1
David, E1
Dominijanni, A1
Gulletta, E1
Genton, P2
Nguyen, VH1
Mesdjian, E2
Marciani, MG1
Spanedda, F1
Placidi, F1
Bassetti, MA1
Romigi, A1
Mattia, D1
Slamberová, R1
Mares, P1
Vorlícek, J1
Selai, CE1
Bawden, HN1
Camfield, CS1
Camfield, PR1
Cunningham, C1
Darwish, H1
Dooley, JM1
Gordon, K1
Ronen, G1
Stewart, J1
van Mastrigt, R1
Chadwick, DW1
Paillard, C1
Vanhulle, C1
Devaux, AM1
Ensel, P1
Monroc-Morval, M1
Blanc, T1
Setterfield, JF1
Robinson, R1
MacDonald, D1
Calonje, E1
Anandam, R1
Jan, MM1
Shaabat, AO1
Nakajima, H1
Guilloton, L1
Burckard, E1
Fresse, S1
Drouet, A1
Felten, D1
Miura, Y1
Amano, S1
Torii, R1
Ihara, N1
Bravaccio, F1
D'Ambrosio, G1
De Rosa, A1
Tata, MR1
Volpe, E1
Rotiroti, D1
Gratteri, S1
Sinopoli, S1
Juliano, M1
Machet, L1
Vaillant, L1
Dardaine, V1
Lorette, G1
Sennoune, S1
Bonneton, J1
Dravet, C1
Roger, J1
Wildin, JD1
Pleuvry, BJ1
Bardy, AH1
Seppälä, T1
Salokorpi, T1
Granström, ML1
Santavuori, P1
van Wieringen, A1
Meijer, JW1
van Emde Boas, W1
Vermeij, TA1
Guberman, A1
Couture, M1
Blaschuk, K1
Sherwin, A1
Keene, DL1
Whiting, S1
Humphreys, P1
Bun, H1
Monjanel-Mouterde, S1
Noel, F1
Durand, A1
Cano, JP1
Dávila-Gutiérrez, G1
Mondragón-Pineda, A1
Alcalá-Negrete, H1
Muñoz, JJ1
De Salamanca, RE1
Diaz-Obregón, C1
Timoneda, FL1
Porter, RJ1
Cornaggia, CM1
Cattabeni, G1
Cerisola, N1
Leozappa, C1
Mascetti, PL1
Massironi, R1
Porro, G1
Manghi, E1
Stéru, L1
Chermat, R1
Millet, B1
Mico, JA1
Simon, P1
Scott, DF3
Reynolds, EH1
Heller, AJ1
Ring, HA1
Larrieu, JL1
Lagueny, A1
Ferrer, X1
Julien, J1
Fraser, AD1
Isner, AF1
Heifetz, SA1
Haigh, JR2
Gent, JP1
Garratt, JC1
Pullar, T2
Minton, NA1
Henry, JA1
Frankel, RJ1
Moffett, A2
Peaker, S1
Feely, MP1
Arranz Peña, MI1
Sanenz Lope, E1
Vajda, FJ1
Bladin, PF1
Parsons, BJ1
Cornaggia, C1
Canevini, MP1
Giuccioli, D1
Pinelli, P1
Pruneri, C1
Canger, R1
Trimble, M1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P)[NCT02565108]Phase 220 participants (Actual)Interventional2016-01-20Completed
Randomized, Double Blind, Placebo Controlled, Parallel Design Phase II b Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies[NCT04406948]Phase 2103 participants (Anticipated)Interventional2023-08-31Not yet recruiting
Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome[NCT00162981]Phase 268 participants (Actual)Interventional2005-10-31Completed
Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073]Phase 22 participants (Actual)Interventional2012-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)

"A TEAE was defined as an adverse event with an onset date on or after the first dose of IMP. If an adverse event (AE) had a partial onset date and it was unclear from the partial date (or the stop date) whether the AE started prior to or following the first dose of IMP then the AE was considered a TEAE. The number of participants who experienced 1 or more severe TEAEs after screening up to Day 71.~A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module." (NCT02565108)
Timeframe: Postdose on Day 2 up to Safety follow-up (Day 71)

InterventionParticipants (Count of Participants)
GWP42003-P 20 mg/kg/Day Dose1
Placebo0

Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33

"The Cmax of CLB and its primary metabolite N-desmethylclobazam (N-CLB) was measured on Day 1 (before beginning GWP42003-P treatment; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 minutes (min), 30 min, 1 hour (h), 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h.~One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose." (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33

,
Interventionng/mL (Geometric Mean)
Cmax: CLB Day 1Cmax: CLB Day 33Cmax: N-CLB Day 1Cmax: N-CLB Day 33Cmax: CLB Dose-normalized Day 1Cmax: CLB Dose-normalized Day 33Cmax: N-CLB Dose-normalized Day 1Cmax: N-CLB Dose-normalized Day 33
GWP42003-P 20 mg/kg/Day Dose3303292060457019.319.2121267
Placebo4404611130132022.023.156.666.1

PK: Area Under The Plasma Concentration-Time Curve Over A Dosing Interval, Where Tau Is The Dosing Interval (AUCtau) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33

"The AUCtau of CLB and its primary metabolite N-CLB was measured on Day 1 (before first GWP42003-P dose; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h.~One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose." (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33

,
Interventionh*ng/mL (Geometric Mean)
AUCtau: CLB Day 1AUCtau: CLB Day 33AUCtau: N-CLB Day 1AUCtau: N-CLB Day 33AUCtau: CLB Dose-normalized Day 1AUCtau: CLB Dose-normalized Day 33AUCtau: N-CLB Dose-normalized Day 1AUCtau: N-CLB Dose-normalized Day 33
GWP42003-P 20 mg/kg/Day Dose26902840183004840015716610702830
Placebo332033101140011500166165571573

PK: Geometric Mean Ratios Of CLB And N-CLB For AUCtau On Day 33 Compared With Day 1

The Day 33 compared to Day 1 geometric mean ratios of CLB and N-CLB were calculated for AUCtau to look for evidence of drug-drug interactions between GWP42003-P/Placebo and CLB and between GWP42003-P/Placebo and N-CLB. A standard 90% CI approach for the between time point ratios of geometric means of AUCtau was carried out on a logarithmic scale using a linear mixed effect model. The no-effect boundary was set between 0.5 and 2.0, and if the 90% CI for the ratio of the geometric means of a PK variable fell within the interval [0.5, 2.0], a lack of meaningful effect was declared. Estimates were back transformed to provide summaries on the original scale. The model included a fixed effect term for PK assessment period. An unstructured covariance matrix was used. Kenward and Roger's method was used to calculate the denominator degrees of freedom for the fixed effects. (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33

,
InterventionRatio (Number)
Geometric Mean Ratio of CLB, AUCtauGeometric Mean Ratio of N-CLB, AUCtau
GWP42003-P 20 mg/kg/Day Dose1.062.64
Placebo0.9961.00

PK: Geometric Mean Ratios Of CLB And N-CLB For Cmax On Day 33 Compared With Day 1

The Day 33 compared to Day 1 geometric mean ratios of CLB and N-CLB were calculated for Cmax to look for evidence of drug-drug interactions between GWP42003-P/Placebo and CLB and between GWP42003-P/Placebo and N-CLB. A standard 90% confidence interval (CI) approach for the between time point ratios of geometric means of Cmax was carried out on a logarithmic scale using a linear mixed effect model. The no-effect boundary was set between 0.5 and 2.0, and if the 90% CI for the ratio of the geometric means of a PK variable fell within the interval [0.5, 2.0], a lack of meaningful effect was declared. Estimates were back transformed to provide summaries on the original scale. The model included a fixed effect term for PK assessment period. An unstructured covariance matrix was used. Kenward and Roger's method was used to calculate the denominator degrees of freedom for the fixed effects. (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33

,
InterventionRatio (Number)
Geometric Mean Ratio of CLB, CmaxGeometric Mean Ratio of N-CLB, Cmax
GWP42003-P 20 mg/kg/Day Dose0.9972.22
Placebo1.051.17

PK: Time To The Maximum Plasma Concentration (Tmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33

"The tmax of CLB and its primary metabolite N-CLB was measured on Day 1 (before beginning GWP42003-P treatment; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h.~One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose." (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33

,
Interventionh (Median)
tmax: CLB Day 1tmax: CLB Day 33tmax: N-CLB Day 1tmax: N-CLB Day 33
GWP42003-P 20 mg/kg/Day Dose1.001.861.503.03
Placebo1.171.582.001.00

A Comparison of the High Dose Group to Low Dose Group of the Percent Reduction in Number of Drop Seizures.

Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and the 4-week maintenance period

InterventionPercent Reduction (Median)
Clobazam Low Dose29
Clobazam High Dose93

Percent Reduction in Number of Drop Seizures.

Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and 4-week maintenance period

InterventionPercent Reduction (Mean)
Clobazam Low Dose10.1
Clobazam High Dose85.2

Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms.

"The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse." (NCT00162981)
Timeframe: Week 3

,
Interventionparticipants (Number)
Very Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch WorseVery Much Worse
Clobazam High Dose151510100
Clobazam Low Dose7993010

Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms.

"The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse." (NCT00162981)
Timeframe: Week 7

,
Interventionparticipants (Number)
Very Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch WorseVery Much Worse
Clobazam High Dose161110100
Clobazam Low Dose66105100

Percent of Patients Considered Treatment Responders Defined as Those With a >= 25%, >= 50%, >= 75%, and 100% Reduction in Drop Seizures.

Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and 4-week maintenance period

,
InterventionPercent of participants (Number)
≥ 25% reduction≥ 50% reduction≥ 75% reduction100% reduction
Clobazam High Dose3230238
Clobazam Low Dose181272

Change in Number of Absence Seizures From Week 8 (Baseline) to Week 12

The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12

InterventionAbscence seizures (Number)
Week 8 Baseline165
Week 12 Verapamil 4mg/kg/Day101

Change in Number of General Tonic-clonic Seizures From Week 8 (Baseline) Visit to Week 12 Visit

The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12

InterventionGeneral tonic-clonic seizures (Number)
Week 8 Baseline39
Week 12 Verapamil 4mg/kg/Day14

Change in Number of Myoclonic Seizures From Week 8 (Baseline) to Week 12

The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12

InterventionMyoclonic seizures (Number)
Week 8 Baseline116
Week 12 Verapamil 4mg/kg/Day175

Reviews

24 reviews available for clobazam and Epilepsy

ArticleYear
Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients.
    International journal of molecular sciences, 2021, Sep-03, Volume: 22, Issue:17

    Topics: Anticonvulsants; Cannabidiol; Carbamazepine; Clobazam; COVID-19; COVID-19 Drug Treatment; Drug Inter

2021
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
    Epileptic disorders : international epilepsy journal with videotape, 2022, 12-01, Volume: 24, Issue:6

    Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Eve

2022
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Experimental neurology, 2023, Volume: 359

    Topics: Adult; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug Resistant Epilepsy; Epilepsies, Myoclonic

2023
Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes.
    The Cochrane database of systematic reviews, 2014, Sep-05, Issue:9

    Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsy; Fructose; Humans; Induct

2014
Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:7

    Topics: Anticonvulsants; Benzodiazepines; Clobazam; Drug Discovery; Epilepsy; Humans

2015
Clobazam for patients with Lennox-Gastaut syndrome and epilepsy.
    Expert review of neurotherapeutics, 2012, Volume: 12, Issue:4

    Topics: Anticonvulsants; Benzodiazepines; Clinical Trials as Topic; Clobazam; Drug Interactions; Electroence

2012
Stiripentol: an example of antiepileptic drug development in childhood epilepsies.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2012, Volume: 16 Suppl 1

    Topics: Anticonvulsants; Benzodiazepines; Child; Clobazam; Cytochrome P-450 Enzyme System; Dioxolanes; Epile

2012
Clobazam.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007, Volume: 4, Issue:1

    Topics: Animals; Anticonvulsants; Benzodiazepines; Brain; Clinical Trials as Topic; Clobazam; Epilepsy; Huma

2007
Clobazam as an add-on in the management of refractory epilepsy.
    The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2

    Topics: Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Humans; Randomized Controlled Trials as Topic

2008
[Benzodiazepines in the treatment of epilepsy].
    L'Encephale, 1983, Volume: 9, Issue:4 Suppl 2

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child, Preschool; Clobazam

1983
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options.
    Seizure, 1995, Volume: 4, Issue:1

    Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam

1995
New anti-epileptic drugs in the 1990s.
    Journal of paediatrics and child health, 1994, Volume: 30, Issue:4

    Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam

1994
Clobazam in the treatment of epilepsy: a review of the literature.
    Epilepsia, 1994, Volume: 35 Suppl 5

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Dose-Response Re

1994
Clobazam for treatment of intractable epilepsy: a critical assessment.
    Epilepsia, 1994, Volume: 35 Suppl 5

    Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clinical Trials a

1994
Investigational antiepileptic drugs for the treatment of childhood seizure disorders: a review of efficacy and safety.
    Epilepsia, 1994, Volume: 35 Suppl 2

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Clinical Trials as

1994
Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs.
    Epilepsia, 1995, Volume: 36 Suppl 2

    Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Cl

1995
[Treatment of the epilepsy: new drugs].
    Revista de neurologia, 1996, Volume: 24, Issue:135

    Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamaz

1996
Fortnightly review: drug treatment of epilepsy.
    BMJ (Clinical research ed.), 1999, Jan-09, Volume: 318, Issue:7176

    Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Barbiturates; Benzodiazepines; Clobazam; Clo

1999
Clobazam in epilepsy.
    Indian journal of pediatrics, 2000, Volume: 67, Issue:1 Suppl

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Clobazam; Epilepsy; Humans

2000
Epileptic encephalopathy.
    Epilepsia, 2001, Volume: 42 Suppl 3

    Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain Diseases; Chil

2001
[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 118, Issue:2

    Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clinical Trials as Topic; Clobazam;

2001
On the use of tranquillisers in epilepsy.
    Epilepsia, 2002, Volume: 43 Suppl 2

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Humans; Tranquilizing Age

2002
Adjunctive therapy in resistant epilepsy.
    Epilepsia, 1988, Volume: 29 Suppl 1

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Resistance;

1988
Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam.
    Epilepsia, 1986, Volume: 27 Suppl 1

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Child; Child, Pre

1986

Trials

25 trials available for clobazam and Epilepsy

ArticleYear
A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:10

    Topics: Adult; Anticonvulsants; Cannabidiol; Clobazam; Double-Blind Method; Drug Interactions; Drug Therapy,

2020
Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*).
    Trials, 2020, Nov-23, Volume: 21, Issue:1

    Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Clobazam; Electroencephalography; Epilepsy; Europe

2020
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study.
    Epilepsia, 2021, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Aged; Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Diazepam; Dru

2021
Response to clobazam in continuous spike-wave during sleep.
    Developmental medicine and child neurology, 2018, Volume: 60, Issue:3

    Topics: Adolescent; Benzodiazepines; Brain Waves; Child; Child, Preschool; Clobazam; Cognition; Electroencep

2018
Clinical and electrocorticographic response to antiepileptic drugs in patients treated with responsive stimulation.
    Epilepsy & behavior : E&B, 2018, Volume: 83

    Topics: Adolescent; Adult; Anticonvulsants; Clobazam; Electrocorticography; Epilepsy; Female; Humans; Lacosa

2018
Clobazam in the treatment of Lennox-Gastaut syndrome.
    Epilepsia, 2009, Volume: 50, Issue:5

    Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Developmenta

2009
Acute administration of benzodiazepines as part of treatment strategies for epilepsy.
    CNS neuroscience & therapeutics, 2011, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Clobazam; Diazepam; Dr

2011
Clobazam monotherapy in drug naïve adult patients with epilepsy.
    Seizure, 2003, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Female

2003
Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB.
    Journal of the neurological sciences, 2007, Dec-15, Volume: 263, Issue:1-2

    Topics: Adult; Anticonvulsants; Benzodiazepines; Clobazam; Dose-Response Relationship, Drug; Epilepsy; Femal

2007
Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants.
    Lancet (London, England), 1982, Jul-10, Volume: 2, Issue:8289

    Topics: Acute Disease; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clinical Tr

1982
Clobazam as adjunctive treatment in drug resistant epilepsy--report on an open prospective study.
    Irish medical journal, 1984, Volume: 77, Issue:8

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child;

1984
Intermittent clobazam for catamenial epilepsy: tolerance avoided.
    Journal of neurology, neurosurgery, and psychiatry, 1984, Volume: 47, Issue:12

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clinical Trials as

1984
Clobazam as adjunctive treatment in refractory epilepsy.
    British medical journal (Clinical research ed.), 1983, Apr-16, Volume: 286, Issue:6373

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clinica

1983
Antiepileptic effects of clobazam in children.
    Brain & development, 1982, Volume: 4, Issue:1

    Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child,

1982
Lack of effect of concomitant clobazam on interictal 123I-iomazenil SPECT.
    Epilepsy research, 1993, Volume: 15, Issue:1

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Brain; Clobazam; Ep

1993
Aggression in children treated with clobazam for epilepsy.
    Clinical neuropharmacology, 1994, Volume: 17, Issue:4

    Topics: Aggression; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child B

1994
Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy.
    Epilepsia, 1998, Volume: 39, Issue:9

    Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; C

1998
Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value?
    Seizure, 1998, Volume: 7, Issue:5

    Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Cyclohexanecarbox

1998
The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy.
    Epilepsy research, 1999, Volume: 33, Issue:2-3

    Topics: Adolescent; Adolescent Behavior; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepin

1999
Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1990, Volume: 17, Issue:3

    Topics: Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Dos

1990
Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1990, Volume: 17, Issue:3

    Topics: Adolescent; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Child, Preschool; Clobaz

1990
Intractable epilepsies. An open trial with Clobazam.
    Acta neurologica, 1989, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clinical Trials as Topic

1989
Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy.
    British journal of clinical pharmacology, 1987, Volume: 24, Issue:6

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy;

1987
Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam.
    Epilepsia, 1986, Volume: 27 Suppl 1

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Child; Child, Pre

1986
Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy.
    Clinical and experimental neurology, 1985, Volume: 21

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child;

1985

Other Studies

110 other studies available for clobazam and Epilepsy

ArticleYear
Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience.
    Epilepsy & behavior : E&B, 2022, Volume: 130

    Topics: Adult; Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Humans; Male; Prospective Studies; Seiz

2022
The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study.
    Epilepsy research, 2022, Volume: 184

    Topics: Anticonvulsants; Child; Clobazam; Cohort Studies; Epilepsy; Humans; Retrospective Studies; Seizures;

2022
Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach.
    Epilepsia, 2022, Volume: 63, Issue:11

    Topics: Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Epilepsy; Levetiracetam; Male; M

2022
Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.
    Epilepsia open, 2023, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Aged; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug-Related Side Effects an

2023
A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy.
    Epilepsia open, 2023, Volume: 8, Issue:3

    Topics: Anticonvulsants; Clobazam; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C

2023
Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet.
    Epilepsia open, 2023, Volume: 8, Issue:3

    Topics: Anticonvulsants; Child; Clobazam; Diet, Ketogenic; Drug Resistant Epilepsy; Epilepsy; Humans; Infant

2023
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies.
    Neurology(R) neuroimmunology & neuroinflammation, 2023, Volume: 10, Issue:6

    Topics: Clobazam; Drug Resistant Epilepsy; Epilepsy; gamma-Aminobutyric Acid; Humans; Precision Medicine; Pr

2023
Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography.
    Stereotactic and functional neurosurgery, 2023, Volume: 101, Issue:6

    Topics: Biomarkers; Clobazam; Deep Brain Stimulation; Drug Resistant Epilepsy; Electrocorticography; Epileps

2023
Gestational Exposure to Benzodiazepines, 3: Clobazam and Major Congenital Malformations.
    The Journal of clinical psychiatry, 2019, 11-26, Volume: 80, Issue:6

    Topics: Abnormalities, Drug-Induced; Anxiety Disorders; Benzodiazepines; Clobazam; Drug Therapy, Combination

2019
Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: A case report on a potential new direction in personalised medicine.
    Seizure, 2020, Volume: 78

    Topics: Anticonvulsants; Clobazam; Enterovirus A, Human; Enterovirus Infections; Epilepsy; Fatal Outcome; Fe

2020
Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome.
    Therapeutic drug monitoring, 2020, Volume: 42, Issue:5

    Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Dioxolanes;

2020
Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database.
    Epilepsia, 2020, Volume: 61, Issue:9

    Topics: Anticonvulsants; Carbamazepine; Clobazam; Clonazepam; Databases, Factual; Drug Therapy, Combination;

2020
Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy.
    Journal of neuro-oncology, 2021, Volume: 151, Issue:2

    Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Clobazam; Drug Therapy, Combination; Epilepsy; Female

2021
CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up.
    Acta neurologica Belgica, 2022, Volume: 122, Issue:1

    Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clobazam; Drug Therapy, Combination; Epilepsie

2022
Interactions between cannabidiol and commonly used antiepileptic drugs.
    Epilepsia, 2017, Volume: 58, Issue:9

    Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Benzodiazepines; Cannabidiol; Child; Child, Prescho

2017
A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy.
    Epilepsia, 2018, Volume: 59, Issue:2

    Topics: Adolescent; Adult; Aged; Alberta; Anticonvulsants; Benzodiazepines; Clobazam; Cohort Studies; Commun

2018
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
    Epilepsy & behavior : E&B, 2018, Volume: 80

    Topics: Adolescent; Anticonvulsants; Attention; Cannabidiol; Cannabis; Child; Child, Preschool; Clobazam; Dr

2018
Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy.
    Therapeutic drug monitoring, 2018, Volume: 40, Issue:4

    Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam;

2018
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
    BMC pregnancy and childbirth, 2018, Jun-14, Volume: 18, Issue:1

    Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine;

2018
Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures.
    Seizure, 2019, Volume: 67

    Topics: Adult; Anticonvulsants; Clobazam; Electroencephalography; Epilepsy; Humans; Patient Discharge; Retro

2019
Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy.
    Therapeutic drug monitoring, 2013, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Asian People; Benzodiazepines; Cl

2013
Electroconvulsive therapy for psychosis in a patient with epilepsy related to hypothalamic hamartoma.
    Epileptic disorders : international epilepsy journal with videotape, 2013, Volume: 15, Issue:3

    Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clobazam; Delusions; Drug Resistance; Electr

2013
Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
    Therapeutic drug monitoring, 2014, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Body Weight; Child; Child, Preschool; Clobazam;

2014
Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19.
    Epilepsy & behavior : E&B, 2014, Volume: 34

    Topics: Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Cytochrome P-450 CYP2C19

2014
Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy.
    Pediatric neurology, 2014, Volume: 51, Issue:1

    Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Dose-Response Relat

2014
Intermittent clobazam prophylaxis in hot water epilepsy is safe and effective: a prospective study.
    Epilepsy research, 2014, Volume: 108, Issue:7

    Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Electroencep

2014
Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:10

    Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam;

2014
Clobazam: the phoenix drug (from the very old to the brand new).
    The Indian journal of medical research, 2014, Volume: 140, Issue:2

    Topics: Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Female; Humans; Male

2014
Effect of clobazam as add-on antiepileptic drug in patients with epilepsy.
    The Indian journal of medical research, 2014, Volume: 140, Issue:2

    Topics: Adolescent; Adult; Ambulatory Care; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Cloba

2014
Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.
    European journal of clinical pharmacology, 2015, Volume: 71, Issue:1

    Topics: Adolescent; Adult; Aged; Anticonvulsants; Asian People; Benzodiazepines; Clobazam; Cytochrome P-450

2015
Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2015, Volume: 19, Issue:2

    Topics: Age of Onset; Anticonvulsants; Autistic Disorder; Benzodiazepines; Cadherins; Child; Clobazam; Cogni

2015
Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series.
    Journal of medical case reports, 2014, Dec-16, Volume: 8

    Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Child; Clobazam; Clonazepam; Epilepsy; Female; Humans

2014
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
    Epilepsia, 2015, Volume: 56, Issue:8

    Topics: Adolescent; Benzodiazepines; Cannabidiol; Child; Child, Preschool; Clobazam; Cytochrome P-450 Enzyme

2015
Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability.
    Therapeutic drug monitoring, 2016, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Child; Ch

2016
Clobazam-induced pedal edema: "An unrecognized side effect of a common antiepileptic drug".
    Epilepsia, 2016, Volume: 57, Issue:3

    Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Clobazam; Edema; Epilepsy; Female; Foot; Humans; Male

2016
The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy.
    Brain & development, 2016, Volume: 38, Issue:8

    Topics: Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Child, Preschool; Clobazam; Clon

2016
Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study.
    Epilepsy research, 2016, Volume: 123

    Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam;

2016
Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.
    The Indian journal of medical research, 2016, Volume: 143, Issue:3

    Topics: Adult; Anticonvulsants; Benzodiazepines; Body Composition; Body Water; Body Weight; Carbamazepine; C

2016
Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq.
    PLoS genetics, 2016, Volume: 12, Issue:10

    Topics: Animals; Benzodiazepines; Chromosome Mapping; Chromosomes; Clobazam; Disease Models, Animal; Epileps

2016
Clobazam in refractory childhood epilepsy.
    Indian journal of pediatrics, 2010, Volume: 77, Issue:3

    Topics: Anticonvulsants; Benzodiazepines; Child; Clobazam; Drug Resistance; Drug Therapy, Combination; Epile

2010
Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year.
    Seizure, 2011, Volume: 20, Issue:5

    Topics: Adolescent; Benzodiazepines; Child; Child, Preschool; Clobazam; Epilepsy; Exanthema; Female; Fructos

2011
Clobazam for the treatment of intractable epilepsy in children.
    Journal of child neurology, 2013, Volume: 28, Issue:1

    Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Epilepsy; Female; F

2013
Clobazam therapy of refractory epilepsy in tuberous sclerosis complex.
    Epilepsy research, 2013, Volume: 104, Issue:3

    Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Epilepsy; Humans; M

2013
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
    Epileptic disorders : international epilepsy journal with videotape, 2012, Volume: 14, Issue:4

    Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr

2012
[Psychomotor slowness of a mentally retarded woman].
    Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:11

    Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Cyclohexan

2001
[Clinical features and treatment of refractory epilepsy in children].
    Rinsho shinkeigaku = Clinical neurology, 2001, Volume: 41, Issue:12

    Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam

2001
Vagus nerve stimulation in a case of epilepsy with CSWSS: respiratory side effects during sleep.
    Epilepsia, 2002, Volume: 43, Issue:10

    Topics: Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Clobazam; Combined Modali

2002
Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19.
    Brain & development, 2004, Volume: 26, Issue:1

    Topics: Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Child; Clobazam; Cytochrome P-450 C

2004
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.
    Brain & development, 2004, Volume: 26, Issue:8

    Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Child; Child, Pr

2004
Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan.
    Epilepsia, 2004, Volume: 45 Suppl 8

    Topics: Anticonvulsants; Benzodiazepines; Clobazam; Clorazepate Dipotassium; Dose-Response Relationship, Dru

2004
Motor impairment on awakening in a patient with an EEG pattern of "unilateral, continuous spikes and waves during slow sleep".
    Epileptic disorders : international epilepsy journal with videotape, 2005, Volume: 7, Issue:2

    Topics: Anticonvulsants; Arm; Benzodiazepines; Child; Clobazam; Electroencephalography; Epilepsy; Ethosuximi

2005
Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats.
    Brain research. Molecular brain research, 2005, Dec-14, Volume: 142, Issue:2

    Topics: Amino Acid Transport System X-AG; Analysis of Variance; Animals; Anticonvulsants; Benzodiazepines; B

2005
Clobazam as add-on therapy in children with epileptic encephalopathy.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2006, Volume: 33, Issue:2

    Topics: Adolescent; Anticonvulsants; Benzodiazepines; Brain; Child; Child, Preschool; Clobazam; Dose-Respons

2006
Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.
    Developmental medicine and child neurology, 2006, Volume: 48, Issue:7

    Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Dose-Response Relationship, Drug; Epil

2006
Oxidative stress in children receiving valproic acid.
    The Journal of pediatrics, 2006, Volume: 149, Issue:5

    Topics: Adolescent; Age Factors; Anticonvulsants; Benzodiazepines; Biomarkers; Canada; Carbamazepine; Case-C

2006
[Epilepsy: which therapy in acute care?].
    Deutsche medizinische Wochenschrift (1946), 2006, Dec-08, Volume: 131, Issue:49

    Topics: Acute Disease; Anticonvulsants; Benzodiazepines; Clobazam; Clonazepam; Diazepam; Epilepsy; Humans; L

2006
The effects of benzodiazepines on chronic epilepsy in man.
    Electroencephalography and clinical neurophysiology. Supplement, 1982, Issue:35

    Topics: Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Electroencephalography; Epilepsy;

1982
[Monotherapy with clobazam in epilepsies in children].
    Presse medicale (Paris, France : 1983), 1983, Apr-16, Volume: 12, Issue:17

    Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child,

1983
Startle-induced epileptic seizures.
    Epilepsia, 1984, Volume: 25, Issue:6

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Child, Preschool;

1984
[Eating epilepsy].
    Orvosi hetilap, 1984, Nov-25, Volume: 125, Issue:48

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Ther

1984
Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients.
    British journal of clinical pharmacology, 1984, Volume: 18, Issue:6

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama

1984
Paroxysmal language disturbance in an epileptic treated with clobazam.
    Neurology, 1983, Volume: 33, Issue:5

    Topics: Adolescent; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; Humans; Mal

1983
[Ataractic treatment in psychiatry and general medicine. Overview of preparations, 3].
    Fortschritte der Medizin, 1983, Jun-09, Volume: 101, Issue:22

    Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Chlorprothixene; Clobaza

1983
Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients.
    British journal of clinical pharmacology, 1981, Volume: 11, Issue:6

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy;

1981
Quantitative determination of clobazam in the plasma of epileptic patients by gas-liquid chromatography with electron-capture detection.
    Journal of chromatography, 1981, Sep-11, Volume: 225, Issue:1

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chromatography, Gas; Cloba

1981
Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance.
    Epilepsia, 1995, Volume: 36, Issue:8

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Ther

1995
Clobazam for intractable pediatric epilepsy.
    Journal of child neurology, 1995, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Cerebra

1995
[Clobazam use in refractory epilepsies in children].
    Arquivos de neuro-psiquiatria, 1993, Volume: 51, Issue:1

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chemotherapy, Adjuvant; Ch

1993
Clobazam in the treatment of epilepsy: prospective follow-up to 8 years.
    Journal of the Royal Society of Medicine, 1993, Volume: 86, Issue:7

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child;

1993
Peripheral benzodiazepine receptors in platelets of epileptic patients.
    British journal of clinical pharmacology, 1993, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; B

1993
The use of clobazam in uncontrolled epilepsy.
    Palliative medicine, 1995, Volume: 9, Issue:4

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carcinoma, Renal Cell; Clo

1995
Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture.
    Epilepsia, 1996, Volume: 37, Issue:8

    Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Cells, Cultured;

1996
Tolerance to anticonvulsant effects of some benzodiazepines in genetically epilepsy prone rats.
    Pharmacology, biochemistry, and behavior, 1996, Volume: 55, Issue:1

    Topics: Acoustic Stimulation; Administration, Oral; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiaz

1996
Interactions of clobazam with conventional antiepileptics in children.
    Journal of child neurology, 1997, Volume: 12, Issue:3

    Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; C

1997
Does antiepileptic therapy affect immune response?
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:2

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama

1998
Carbamazepine intoxication with negative myoclonus after the addition of clobazam.
    Epilepsia, 1998, Volume: 39, Issue:10

    Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Cloba

1998
Changes of the EEG paroxysmal pattern during felbamate therapy in Lennox-Gastaut syndrome: a case report.
    The International journal of neuroscience, 1998, Volume: 95, Issue:3-4

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Drug Therapy,

1998
Clobazam exerts an anticonvulsant action in immature rats.
    Physiological research, 1998, Volume: 47, Issue:4

    Topics: Aging; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Electric Stimulatio

1998
Report of a pragmatic trial comparing clobazam and "standard" treatment in childhood epilepsy.
    Epilepsia, 1999, Volume: 40, Issue:4

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Canada; Child; Clobazam; Epilepsy; Humans; Pa

1999
[Recurrence of herpes simplex encephalitis].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1999, Volume: 6, Issue:10

    Topics: Acyclovir; Anti-Anxiety Agents; Anti-Inflammatory Agents; Anticonvulsants; Antiviral Agents; Benzodi

1999
Coma-induced bullae and sweat gland necrosis following clobazam.
    Clinical and experimental dermatology, 2000, Volume: 25, Issue:3

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Coma; Epilepsy; F

2000
Clobazam for the treatment of intractable childhood epilepsy.
    Saudi medical journal, 2000, Volume: 21, Issue:7

    Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Cohort Studies; Epi

2000
[Epileptic crisis after antimalaria chemoprophylaxis with chloroquine].
    Presse medicale (Paris, France : 1983), 2001, Nov-24, Volume: 30, Issue:35

    Topics: Anti-Anxiety Agents; Anticonvulsants; Antimalarials; Benzodiazepines; Chloroquine; Clobazam; Epileps

2001
Clobazam shows a different antiepileptic action profile from clonazepam and zonisamide in Ihara epileptic rats.
    Epilepsy research, 2002, Volume: 49, Issue:3

    Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Circadian Rhythm; Clobazam; Clonazep

2002
[The anti-epileptic properties of a diazepine drug (clobazam). Preliminary results].
    Acta neurologica. Quaderni, 1979, Volume: 39

    Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Clobazam; Epilepsy; Epilepsy,

1979
Tolerance to anticonvulsant effects of clobazam, diazepam, and clonazepam in genetically epilepsy prone rats.
    Advances in biochemical psychopharmacology, 1992, Volume: 47

    Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepino

1992
Patch testing with clobazam: relapse of generalized drug eruption.
    Contact dermatitis, 1992, Volume: 26, Issue:5

    Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Erupt

1992
Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy.
    Therapeutic drug monitoring, 1992, Volume: 14, Issue:4

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama

1992
Tolerance to the anticonvulsant effects of clobazam in mice.
    Neuropharmacology, 1992, Volume: 31, Issue:2

    Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepino

1992
Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy.
    Brain & development, 1991, Volume: 13, Issue:3

    Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child,

1991
Pilot study to determine the interaction of oxiracetam with antiepileptic drugs.
    Clinical pharmacokinetics, 1990, Volume: 18, Issue:4

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Clob

1990
Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam.
    Pharmacology & toxicology, 1990, Volume: 67, Issue:2

    Topics: Adolescent; Adult; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepin

1990
[Usefulness of clobazam in the treatment of refractory epilepsy in children].
    Boletin medico del Hospital Infantil de Mexico, 1990, Volume: 47, Issue:10

    Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chemical Pheno

1990
The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites.
    British journal of clinical pharmacology, 1990, Volume: 29, Issue:6

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Chromatogra

1990
Mechanisms of action of new antiepileptic drugs.
    Epilepsia, 1989, Volume: 30 Suppl 1

    Topics: Acetamides; Acetates; Amines; Aminocaproates; Aminopyridines; Anti-Anxiety Agents; Anticonvulsants;

1989
Oral benzodiazepines as prophylaxis for epilepsy.
    Drug and therapeutics bulletin, 1986, Jun-16, Volume: 24, Issue:12

    Topics: Administration, Oral; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Clonazepam;

1986
Comparative study in mice of ten 1,4-benzodiazepines and of clobazam: anticonvulsant, anxiolytic, sedative, and myorelaxant effects.
    Epilepsia, 1986, Volume: 27 Suppl 1

    Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Epileps

1986
Clobazam in chronic epilepsy.
    Lancet (London, England), 1988, Aug-06, Volume: 2, Issue:8606

    Topics: Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; Humans

1988
Clobazam for epilepsy.
    Lancet (London, England), 1988, Sep-03, Volume: 2, Issue:8610

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chronic

1988
[Epilepsy with continuous discharges during slow-wave sleep. Treatment with clobazam].
    Revue d'electroencephalographie et de neurophysiologie clinique, 1986, Volume: 16, Issue:4

    Topics: Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Carbamazepine; Child; Child, Preschool; Clo

1986
Tissue distribution of ethosuximide and clobazam in a seizure related fatality.
    Journal of forensic sciences, 1988, Volume: 33, Issue:4

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Chromatography, Gas

1988
Disappointing results of increasing benzodiazepine dose after the development of anticonvulsant tolerance.
    Journal of neurology, neurosurgery, and psychiatry, 1988, Volume: 51, Issue:7

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Dose-Resp

1988
Fatal paracetamol poisoning in an epileptic.
    Human toxicology, 1988, Volume: 7, Issue:1

    Topics: Acetaminophen; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Cytochrome

1988
The long-term effect of clobazam as adjunctive therapy in epilepsy.
    Acta neurologica Scandinavica, 1988, Volume: 77, Issue:6

    Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Clobazam; Electroencephalogra

1988
Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures.
    Epilepsia, 1986, Volume: 27 Suppl 1

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child, Preschool; Clobaz

1986
On the anticonvulsant and psychotropic properties of clobazam--a preliminary study.
    Epilepsia, 1986, Volume: 27 Suppl 1

    Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; Female; Humans;

1986
Benzodiazepines in the treatment of children with epilepsy.
    Epilepsia, 1986, Volume: 27 Suppl 1

    Topics: Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Child, Preschool; Clobazam; Clonazep

1986
Determination of clobazam and its N-demethyl metabolite in serum of epileptic patients.
    Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie, 1986, Volume: 24, Issue:9

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chromatography, Gas; Cloba

1986
Monotherapy and polytherapy for intractable epilepsies.
    Italian journal of neurological sciences, 1985, Volume: 6, Issue:2

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Clobazam; D

1985
Development of tolerance to anticonvulsant effect of clobazam.
    Journal of neurology, neurosurgery, and psychiatry, 1985, Volume: 48, Issue:3

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Therapy, Co

1985